Macroscopic Hematuria Segment has the Largest Share of Type in the South & Central America Hematuria Treatment Market during 2021–2028

According to our latest study on “South & Central America Hematuria Treatment Market Forecast to 2028 – COVID-19 Impact and Analysis – by Type, Treatment, Indication, and End User,” the market is projected to reach US$ 65.7 million by 2028 from US$ 57.8 million in 2021; it is expected to grow at a CAGR of 1.8% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the high prevalence of hematuria- associated indications, increasing awareness about treatment options and improving healthcare expenditure are factors propelling the hematuria treatment market. However, the undiagnosed cases of associated indications may hamper the growth of the South & Central America hematuria treatment market in the forecast period.

The SARS-CoV-2 pandemic had a sudden, dramatic impact on the healthcare of the SCAM region. The COVID-19 pandemic has shifted the accepted and routine treatment of elective cases in hospital administration. South and Central America are no exception. Strict social distancing procedures now apply, with patients being admitted to the clinic unaccompanied and individually. CoViD-19 has changed everyday life almost all over the world. Overall, the magnitude of this disruption is due to individual fears and government-level actions relative to the local impact of the pandemic. However, there may be times when restrictive measures are put in place in the early stages, when the rapid evolution of the problem is unknown, to ensure the community's health. In Argentina, this was the situation that paralyzed programmed medical care. Such restrictions are likely to have a negative impact on the research and development activities, which would directly restrain the growth of the hematuria treatment market in the region.

Based on type, the South & Central America hematuria treatment market is bifurcated into macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger’s hematuria. In 2021, the macroscopic hematuria segment is estimated to account for the largest market share. However, microscopic hematuria segment is estimated to register the highest CAGR during forecast period. Macroscopic hematuria is also known as gross hematuria. It is diagnosed by various methods such as blood tests, kidney biopsy, and others diagnosis techniques.

AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc.,Sun Pharmaceutical Industries Ltd, and Boehringer Ingelheim International GmbH are among the leading companies in the South & Central America hematuria treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, AstraZeneca, in September 2021, the new plant will allow for late-stage development and early commercial supply, adopting state of the art process technology and digital innovation that is designed to meet the needs of the Company’s new medicines pipeline with speed and agility.

The market for hematuria treatment market is segmented into type, treatment, Indication, and end user. Based on type, the South & Central America hematuria treatment market is segmented into macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger’s hematuria. Based on treatment, the hematuria treatment market is segmented drugs, therapies, and others. Based on indication, the hematuria treatment market is segmented into urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, and menstruation. Based on end user, the hematuria treatment market is segmented into hospitals, clinics, and Ambulatory Surgical Centers, and others. Geographically, the hematuria treatment market is segmented into South & Central America (Brazil, Argentina, Rest of South & Central America).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com